Cloudbreak Pharma Announces Top-Line Results From Phase 3 CBT-001 Study
Story updates
01:01:20 AM UTC
SquawkNews
Both doses of CBT-001 demonstrated statistically significant improvements in conjunctival hyperemia
01:01:52 AM UTC
SquawkNews
Both doses of CBT-001 demonstrated statistically significant improvements in conjunctival hyperemia at Month 3 versus vehicle (p<0.001), with improvement observed as early as Week 2 and maintained through Month 12Both doses also demonstrated statistically significant prevention of progression of pt…
01:02:10 AM UTC
SquawkNews
In Phase 3, both CBT-001 doses significantly improved conjunctival hyperemia at Month 3 and prevented pterygium lesion progression at Month 12 versus vehicle (p<0.001). The company plans to meet with the FDA to discuss next steps.Material DetailsContext by AI AnalystThis is a Phase 3 topline clinic…